English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduStem cell researcher Teresa Bowman, Ph.D., has been appointed chair of the department of developmental & molecular biology (DMB) at Albert Einstein College of Medicine after a comprehensive national search. Dr. Bowman will begin her new role on December 1, following the longtime leadership of Richard Stanley, Ph.D.
Tag: Cancer Research
Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.
Study finds common breast cancer treatments may speed aging process
The findings, published in the Journal of the National Cancer Institute, show that markers of cellular aging—such as DNA damage response, cellular senescence, and inflammatory pathways—significantly increased in all breast cancer survivors, regardless of the type of treatment received.
Scientists Discover That Special Immune Cells Stop Metastatic Cancer
A research team at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) has discovered a natural immune mechanism in mice that stops escaped cancer cells from developing into tumors elsewhere in the body. The findings were published today in the journal Cell.
Dr. Roger Lo awarded NIH grant to tackle melanoma treatment resistance
UCLA’s Dr. Roger Lo was awarded a $2 million grant from the National Institutes of Health to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.
Case closed: Neutrons settle 40-year debate on enzyme for drug design
Scientists at ORNL used neutrons to end a decades-long debate about an enzyme cancer uses. Their findings can support the design of an inhibitor that can target aggressive cancers.
Drilling Down to the Details in Cancer Research
When an aggressive cancer launches an invasion on the human body, anything that can be done to slow down or better understand that fast-paced assault is going to be a bonus.
Vulnerable Patients Have a Decreased Mortality Risk When Treated at Commission on Cancer-Accredited Hospitals
Highly vulnerable patients treated at hospitals accredited by the ACS Commission on Cancer were more likely to receive guideline-based care and less likely to die.
Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024
Novel treatments, including targeted therapies and antibody drug conjugates, as well as research into improving quality of life for patients with breast cancer, headline studies led by Dana-Farber Cancer Institute and presented at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.
New law regulating out-of-pocket drug spending saves cancer patients more than $7,000 a year, study finds
As prescription oral chemotherapies have become a common form of cancer treatment, some patients were paying more than $10,000 a year for medications. A new study finds that efforts to cap prescription drug spending are yielding significant out-of-pocket savings for these patients.
Cancer Research Institute (CRI) Appoints Alicia Zhou, PhD, as Chief Executive Officer to Advance Next Generation of Cancer Immunotherapy Science and Innovation
The Cancer Research Institute (CRI) has appointed Alicia Zhou, PhD, as its new Chief Executive Officer (CEO).
Cancer Research in Space for Life on Earth: Wake Forest Institute for Regenerative Medicine Selected Through International Space Station National Lab Solicitation in Partnership with NASA
The Wake Forest Institute for Regenerative Medicine (WFIRM) is honored to announce its selection for a pioneering cancer research project that will take place aboard the International Space Station (ISS).
Researchers identify factor that drives prostate cancer-causing genes
Researchers at the University of Michigan Health Rogel Cancer Center have uncovered a key reason why a typically normal protein goes awry and fuels cancer. They found the protein NSD2 alters the function of the androgen receptor, an important regulator of normal prostate development.
TGF-Beta and RAS Signaling Are Both Required for Lung Cancer Metastasis, Study Finds
MSK researchers have identified two signaling pathways that work together to spur the spread of lung cancer. Taking away one of those signals could help slow or stop metastasis, findings in animal models suggest.
Global Experts Converge at CICON24 to Unveil Groundbreaking Advances in Cancer Immunotherapy, September 8-11, 2024 at National Harbor, MD
CRI is co-hosting CICON24 to illuminate pioneering advances in cancer immunotherapy research starting September 8 in National Harbor, MD.
Age-Related Changes in Male Fibroblasts Increase Treatment-Resistant Melanoma
Age-related changes in the fibroblasts, cells that create the skin’s structure, contribute to the development of aggressive, treatment-resistant melanoma in males, according to research in mice by the Johns Hopkins Kimmel Cancer Center.
Novel Study Reveals How Aging Immune System Fuels Cancer Growth, Potentially Opening New Avenues for Prevention
A novel study by researchers at the Icahn School of Medicine at Mount Sinai addresses a critical yet under-explored question in cancer research: Why is aging the biggest risk factor for cancer? The study reveals how an aging immune system spurs tumor growth, offering new insights into cancer prevention and treatment, especially for older adults.
MSK Research Highlights, September 3, 2024
New research from Memorial Sloan Kettering Cancer Center (MSK) uses cryo-electron microscopy to shed new light on the ubiquitin; could help predict the risk of blood clots in cancer patients; reveals why micronuclei burst, accelerating aggressive cancers; and surveys healthcare providers about the benefits and risks of commercial genetic testing.
SHRO Scientist Named FDA-AACR Cancer Research Fellow
Canio Martinelli, M.D., MSc, GYN-OB resident at the University of Messina and visiting Ph.D. student in Translational Molecular Medicine and Surgery at the Sbarro Health Research Organization (SHRO), Temple University, has been honored with the 2024-2025 FDA-AACR Oncology Educational Fellowship.
Americans face disparities in exposure to tobacco on streaming platforms
Tens of millions of Americans are being exposed to tobacco content on streaming services, according to new research from The University of Texas MD Anderson Cancer Center.
Rutgers Researchers Explore Potential for Artificial Intelligence (AI) in Biomedical Science
New Brunswick, N.J., August 21, 2024 – Generative artificial intelligence (AI) powered by human language has made remarkable progress and gained widespread use through tools such as ChatGPT. While it is mostly known for helping with reading and writing, scientists are…
Preliminary study shows potential of Manuka honey as a nutraceutical for breast cancer
A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that Manuka honey could potentially be an alternative, natural option for breast cancer prevention and treatment— particularly for estrogen receptor (ER)-positive breast cancer, the most common subtype of breast cancer that accounts for about 70–80% of all breast cancer cases.
Comprehensive atlas of normal breast cells offers new tool for understanding breast cancer origin
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have completed the most extensive mapping of healthy breast cells to date. These findings offer an important tool for researchers at IU and beyond to understand how breast cancer develops and the differences in breast tissue among genetic ancestries.
MD Anderson recognizes outstanding faculty
The University of Texas MD Anderson Cancer Center last night recognized over 100 faculty members at its annual Celebration of Faculty Excellence awards ceremony, acknowledging their compassionate care, exceptional contributions to their fields and the distinction they have brought to the institution.
Demystifying APE1: New findings on direct activation of ATM signaling by DNA single-strand breaks
Whereas ATM signaling is well known to be activated by DNA doubles-strand breaks, this study provides new evidence that ATM signaling is directly activated by DNA single-strand breaks and activated and regulated by APE1 in eukaryotic systems.
Maui attorney turns brain cancer journey into hope for others
Newirth beat the odds thanks to a novel cancer vaccine developed by UCLA neurosurgeon Linda Liau, MD, PhD. And now, he’s doing everything in his power to support cutting-edge cancer research and provide extra support to individuals going through cancer treatment.
Study suggests an MRI may help doctors predict more aggressive prostate cancer in patients
New Corewell Health™ research suggests an MRI scan can help predict whether patients with intermediate-risk prostate cancer (cancer confined to the entire prostate) may have more aggressive cancer in five years.
Cancer Research Institute Awards Over $22 Million in Grants to Fuel Immunotherapy Innovations
CRI awarded over $22 million to leading cancer immunotherapy researchers in the 2024 fiscal year, amounting to 64 awards at 42 institutions.
MSK Research Highlights, July 31, 2024
New research from Memorial Sloan Kettering Cancer Center (MSK) showed giving chemotherapy shortly after a stem cell or bone marrow transplant from a less than perfectly matched donor greatly reduces the chances that the patient will develop graft-versus-host disease (GVHD); and sheds new light on cell state changes in prostate cancer.
New research discovers a new combination of therapy for people with a type of leukemia, leading them to live longer
In a new multicenter international study led by the Mayo Clinic Comprehensive Cancer Center, researchers found that people with the B-cell precursor subtype of acute lymphoblastic leukemia (BCP-ALL), who also lacked a genetic abnormality known as the Philadelphia chromosome and were in remission with no trace of cancer, showed significantly higher survival rates when blinatumomab was added to their chemotherapy treatment.
NCCN Oncology Research Program Celebrates 25 Years of Advancing Cancer Science
The National Comprehensive Cancer Network (NCCN)’s research arm achieves major milestone, showcasing years of success in fostering innovation and knowledge discovery that improves the lives of patients with cancer.
Landmark Study Shows Elevated Cancer Risk for Women with Endometriosis
Women with endometriosis are four times more likely to develop ovarian cancer, and those with more severe cases are at an even greater risk.
Dr. Tanya Stoyanova receives $1.8 million to reveal new treatment strategies for advanced prostate cancer
Dr. Tanya Stoyanova, associate professor of molecular and medical pharmacology and urology at the David Geffen School of Medicine at UCLA(Link is external) (Link opens in new window), was awarded a $1.8 million grant from the National Cancer Institute to identify new drivers and test new therapeutic strategies for advanced treatment-resistant prostate cancer.
Cancer researchers receive grant to combat aggressive kidney cancer
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center(Link opens in new window) have received an $800,000 grant from the V Foundation to find new ways to treat and prevent a severe form of kidney cancer associated with a hereditary syndrome caused by mutations in the fumarate hydratase (FH) gene.
MD Anderson Research Highlights for July 11, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Call for Papers: Theme Issue: Artificial Intelligence in Oncology
JMIR Publications invites submissions to a new theme issue titled “Artificial Intelligence in Oncology” in its premier open access journal JMIR Bioinformatics and Biotechnology indexed in PubMed Central and PubMed, SCOPUS, Sherpa/Romeo, DOAJ and EBSCO/EBSCO Essentials.
SHRO Award Announcement June 28 2024
The annual Taobook International Literary Festival held in Taormina, Sicily has announced their 2024 Taobuk Awards, naming Professor Antonio Giordano, MD, PhD, President and Founder of the Sbarro Health Research Organization (SHRO), this year’s recipient of the Da Vinci Award.
Fred Hutch launches new scientific training program for high school and middle school teachers
Fred Hutch Cancer Center has launched (PS2@FH), a new summer research program that trains middle school and high school teachers in Fred Hutch labs to expand hands-on learning experiences they can take back to the classroom.
Researchers report first effective use of immunotherapy for most common subtype of colorectal cancer
These clinical trial results point to the first safe and effective use of immunotherapy for patients with microsatellite stable colorectal cancer, the most common subtype of the disease. The encouraging results of this phase I trial have prompted Dana-Farber investigators to move forward with a phase III trial of this immunotherapy combination.
The Harvey L. Neiman Health Policy Institute Launches Cancer Equity Compass
The Harvey L. Neiman Health Policy Institute announces the public launch of a new online tool that reveals the overlap between cancer disparities and social determinants of health (SDOH) using advanced heat maps of U.S. counties. The Cancer Equity Compass can identify high-opportunity targets for policies and programs to achieve equitable health outcomes in underserved populations.
Anti-inflammatory drug celecoxib could reduce risk of colon cancer recurrence for a subset of patients
An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation.
Pediatric brain tumors rely on different metabolic “route” to fuel treatment resistance
Researchers at the University of Michigan Health Rogel Cancer Center are one step closer to understanding how pediatric DIPG tumors work.
Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant
Roswell Park Comprehensive Cancer Center has earned its most highly rated grant from the National Cancer Institute (NCI). The NCI renewed Roswell Park’s status as a Comprehensive Cancer Center – a designation held by less than 4% of cancer centers- awarding Roswell Park the highest possible “Exceptional” rating as it renewed a grant Roswell Park has successfully competed for since 1972.
Clinical trials show promise in treating central nervous system lymphoma, breast cancer, and glioblastoma
Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.
ASCO: Large precision oncology study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of U.S. veterans
A new study(Link is external) (Link opens in new window) led by a UCLA-VA collaborative team looking at the landscape of genomic alterations in more than 5,000 veterans with metastatic prostate cancer uncovered differences in the genomic makeup of cancer cells that were associated with race and ethnicity.
From Bench to Bedside on Ovarian Cancer
May 22nd marked a significant milestone in the collaborative efforts to combat ovarian cancer as the “International Dialogue on Ovarian Cancer, from Bench to Bedside” congress was held, bridging the gap between primary research and clinical practice.
Hearst Health Prize judging panel selects two finalists; Winner to be announced at UCLA Health Data Day
Hearst Health and the UCLA Center for SMART Health today announced that a panel of expert judges has selected Mount Sinai Health System and The University of Texas MD Anderson Cancer Center as the 2024 Hearst Health Prize finalists. The winner will be announced at UCLA Health Data Day on June 4, 2024.
Dr. Daniel Geynisman Named New Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network
Daniel M. Geynisman, MD, is being announced the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network. Dr. Geynisman, Chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, has a long history of working with NCCN in a variety of roles.
Wetter Recognized for Exemplary Leadership in Cancer Equity Initiatives
David Wetter, PhD, has been honored for pioneering cancer health equity strategies, transforming research into practical solutions, and fostering vital community partnerships for underserved populations and rural communities.
Interdisciplinary team of UWF faculty help write the rules on cancer prevention in Florida
UWF faculty, serving as evaluators for Florida’s Cancer Prevention and Control Program since 2018, recently had their contract renewed for $680,000 over four years due to excellent performance, as acknowledged by the CDC.